SUMMARY High doses of intravenous desferrioxamine infused over a short period of time induce a large faecal and urinary iron excretion but also produce retinal abnormalities that are characterised by decreased amplitude on electroretinography and defective dark adaptation. This regimen also results in high faecal iron, zinc, and copper excretion, and reduced granulocyte zinc concentrations and alkaline phosphatase activity. The retinal abnormalities may be related to the zinc and copper deficiency and/or iron depletion 'per se' which interferes negatively with critical iron dependent enzymes.
Subcutaneous infusion of desferrioxamine is the most efficient method for reducing the iron burden in patients with thalassaemia major who are transfusion dependent. 1 The daily infusion of 40-60 mg/kg over 12 hours for six days a week is usually sufficient to obtain iron balance.'v Because some patients fail to comply with this regimen the additional administration of large doses by intravenous infusion has been proposed. 3 High doses of desferrioxamine, either by intravenous or subcutaneous administration, however, may result in optic neuropathy or high frequency sensorineural hearing loss, or both.7 8 Likewise, in rabbits anaesthetised with urethane, the intravenous infusion of large doses of desferrioxamine produced a reversible reduction in the amplitude of the electroretinogram.9 Toxic concentrations are probably reached when the dose of desferrioxamine administered is disproportionately high in relation to the amount of iron available for chelation. In these conditions desferrioxamine may chelate critical trace elements such as copper and zinc,10 the depletion of these elements may be responsible for the neurotoxic effect of the drug.
In this study we monitored the development of ocular abnormalities and possible zinc or copper depletion, or both, in a group of patients with thalassaemia major who were chelated with desferrioxamine by a combination of traditional daily subcutaneous infusion and monthly intravenous administration of large doses because of failure to comply with the regimen of subcutaneous administration.
Patients and methods
Fifteen children, aged from 9 to 16 years, with transfusion dependent thalassaemia major and moderate iron overload (serum ferritin concentrations from 1100 to 2000 [tg/l), because of low compliance with daily infusion of subcutaneous desferrioxamine, were treated by a combination of traditional daily subcutaneous infusion and monthly intravenous administration of very large doses according to a previously published scheme.11 Each patient was treated for 10 consecutive months but the balance study (see later) was carried out only once.
The dose of desferrioxamine for subcutaneous infusion was 40-60 mg/kg over a period of 12 hours each night for six days a week. The intravenous infusion was given over a period of 24 hours at the dosage of 10-12 g (200-450 mg/kg) dissolved in 750 ml of 5% glucose solution. Urinary and faecal iron concentrations, zinc and copper excretion, serum zinc pattern, leukocyte zinc concentrations, and alkaline phosphatase activities were analysed only once, as detailed later, before and after the infusion of intravenous desferrioxamine when we introduced the combination of both intravenous and subcutaneous administration. 250 Depletion of trace elements and acute ocular toxicity in patients with thalassaemia 251
Ophthalmic evaluation was also carried out before and after the termination of the infusion, but this assessment was repeated from two to three times at times of successive intravenous infusion and again one, two, and three months after we interrupted the intravenous infusions while continuing the subcutaneous administration.
OPHTHALMOLOGIC ASSESSMENT
The ophthalmic assessment included determination of the best corrected visual acuity by standard methods, pupillary reaction, ocular motility, slit lamp examination for changes in the anterior segment, and visual field measurement on a calibrated Goldman kinetic perimeter with light intensity regulated at 31-5 apostilb. A In order to carry out copper, zinc, and iron balance studies each patient was admitted to the hospital for a week. With the aim of eliminating any residual effect of the subcutaneous infusion the day before admission the daily infusion of subcutaneous desferrioxamine was interrupted. While in the hospital the patients were on a strict controlled diet containing roughly 8-10 mg/day iron, 0-1 mg copper/kg body weight, and 0-3-0-4 mg zinc/kg body weight. Diet and collection of the urine and stool were carefully controlled by nurses who were specifically instructed to avoid any faecal contamination with urine. Collection periods of stools were defined by. administering radio-opaque markers.
Precautions against environmental contamination were taken for all diet, blood, urine, and stool collections and analyses. Specimens were stored only in plastic containers and only low mineral content water and ultra high purity reagents were used in sample and standards preparation; before use, all glassware and plastic containers were acid washed in 1-0 N hydrochloric acid for 30 minutes and rinsed six times in deionised water.
Blood samples from peripheral veins were collected with plastic syringes and stainless steel needles and put into plastic tubes. Serum and granulocyte zinc concentrations and granulocyte alkaline phosphatase activity were measured in samples taken before and at the end of the intravenous infusion as well as one month later.
Basal iron, zinc, and copper excretion were evaluated in urine and faeces collected for three days before the infusion of desferrioxamine. The effect of this infusion was determined by measuring these elements in the urine and faeces collected on the day of the infusion as well as three days after. During this study period the subcutaneous infusion was interrupted.
An aliquot of the preinfusion and postinfusion urinary pools was prepared and frozen for further analysis. The faeces were homogenised with a known amount of deionised water. An aliquot was removed and dried at 100°C overnight and then ashed in a muffle furnace at 550°C and left overnight. The resultant ash was dissolved with 10% hydrochloric acid, transferred to a volumetric flask, and made up to volume with demineralised water.
Serum, urinary, and faecal iron, zinc, and copper were determined by atomic absorption (IL 551 Spectrophotometer). Granulocyte alkaline phosphatase activity was assayed with p-nitrophenylphosphate as substrate according to It-Koon and Moss.14 Granulocytes were separated from the other blood cells according to Boyum 
zinc pattern were observed between the three groups of subjects investigated.
The effects of desferrioxamine infusion on iron, zinc, and copper excretion are summarised in fig 3. After infusion of desferrioxamine there was a significant (p<0001) increase of mean urinary and faecal iron excretion. On average 45% of the iron was eliminated through the urine and 55% with the stools. After the infusion, faecal and urinary zinc and copper excretion were also significantly increased (p<0-001 and <005, respectively). Considering all the patients together no significant correlation was observed between zinc and iron elimination both in faeces and urine.
If the patients were divided according to the abnormalities shown on their electroretinograms-that is, the first group without abnormalities, the second group with transitory alterations after intravenous infusion, and the third group with permanent abnormalities-it can be seen that the second group of patients had significantly (p<005) higher mean urinary zinc elimination compared with the first group; there were no differences observed in iron and copper elimination. Mean faecal excretions of all the three trace elements were significantly higher in the second group (p<0-001 for iron and zinc; p<0.01 for copper) than in the first group (p<0-01). In the second group there was an inverse correlation between total zinc and iron elimination; this, however, did not reach significance. Those subjects who had persistent abnormalities on their electroretinograms had less iron, copper, and zinc excretion both in urine and faeces when compared with the other two groups.
In all patients granulocyte zinc content and The fluctuations in the serum zinc concentration that are seen during infusion of desferrioxamine are probably not related to administration of the drug as they are very similar to the daily variations in serum zinc concentrations found in normal subjects (circadian rhythm).17
In this investigation large doses of intravenous desferrioxamine produced a consistent increase in iron excretion as has been found in previous studies3 1 but resulted also in increased elimination of zinc and copper. Intravenous desferrioxamine had more effect on the faecal loss of iron, zinc, and copper than it had on their urinary loss. We can exclude the possibility that this pattern may be due to urine contamination of faeces during collection because during the balance study the patients were in the hospital and urine and faecal collections were carefully controlled by a nurse who had been adequately instructed. Furthermore it is already known from a study carried out by Pippard et al that large doses of desferrioxamine result in an increase of faecal iron loss but have little effect on urinary elimination. 18 An inverse but not significant correlation between iron and zinc excretion was observed solely in those subjects with transient abnormalities on electroretinography.
Increased copper and zinc excretion may be explained by assuming that the rapid infusion of large doses of desferrioxamine left a certain amount of the drug non-iron chelated and thus able to chelate these trace elements. Accordingly granulocyte alkaline phosphatase activity, which is one of the best indicators of the zinc content of the organism'9 decreased significantly after the infusion of desferrioxamine. We cannot exclude, however, that at least partially, the decrease of leukocyte alkaline phosphatase activity may be caused by a possible interference of residual desferrioxamine in the assay of this zinc dependent enzyme.
The depletion of iron, zinc, and copper may be related to the retinal abnormalities. help cause the production of retinal anomalies. We have excluded the possibility that ocular abnormalities in our patients were related to a diabetic or prediabetic condition via the disruption of the integrity of the blood-retinal barrier, as has been proposed,28 because none of our patients had a reduced glucose tolerance (data not shown).
A limited number (three out of 15) of the patients investigated showed persistent abnormalities on electroretinography. Because it is difficult to assess the compliance to treatment we do not know whether these patients differed from those with transient abnormalities in the amount of desferrioxamine they received by the daily subcutaneous infusion in the years preceding the trial. Those patients with persistent abnormalities did not differ, however, from those with transient modifications in the serum ferritin concentrations, the zinc content, and alkaline phosphatase activity of leukocytes, but showed lower zinc and iron excretion after intravenous infusion of desferrioxamine. This may indicate the presence of less iron accumulation and a borderline zinc reserve, which may nevertheless result in defective function of those tissues, such as the retinal epithelium, which are most sensitive to zinc depletion.
In conclusion, administration of large doses of desferrioxamine by intravenous infusion are able to produce in iron overloaded thalassaemia patients a very large iron excretion but they also induce excretion of trace elements such as copper and zinc and cause transient ocular abnormalities. For those patients treated with this regimen ophthalmological evaluation is recommended for determining early retinal toxicity induced by desferrioxamine. Further studies are needed in order to assess whether a reduction of the desferrioxamine dosage may avoid these toxic effects. 
